Research to guide rural palliative care practice is sparse. Approaches to telehealth, community- academic partnerships, and training rural health care professionals show promise, but more research is needed to determine best practices for providing palliative care to patients living in rural settings.

Survivorship care at MSTI meets new standards, allows for patient engagement and satisfaction, and improves care coordination; costs are covered by reimbursement.

Peripheral neuropathy was the most common BV-associated AE across clinical trials. Other clinically relevant AEs included neutropenia, infection, and infusion-related reactions. Awareness of and preparedness for these common BV-associated AEs and other less common but significant AEs will help nurse clinicians and patients maximize the clinical benefit for patients receiving BV.

Providing palliative care to persons living in rural areas across the globe presents significant barriers including: transportation, geographical and economic challenges, and often a lack of local clinicians with expertise and resources to provide complex palliative care services. Strategies are being designed and successfully implemented to meet the challenges of rural palliative care, including telehealth, phone-based care, specially trained lay community workers, and academic-community partnerships.

In line with Article 20 (9) of the Tobacco Products Directive (TPD) 2014/40/EU, a guidance document outlining a reporting system of suspected adverse effects from electronic cigarettes and their refill liquids was produced by Work Package 4 entitled ‘Integration into national policies and sustainability’ of the Joint Action on Tobacco Control (JATC). The JATC was a European project that lasted three years (2017–2020), with the general objective of providing support for the implementation of the TPD throughout the 27 European Union Member States (EU MS). The reporting system described in the guidance document includes a short reporting template for the reporting of adverse effects on human health from electronic cigarettes and refill liquids, both by Economic Operators (EO) and by National Competent Authorities (NCA). The present guidance document aims at providing the necessary steps and modalities that each MS should follow if involved in the development of a system for the reporting of suspected adverse effects on human health from electronic cigarettes and refill liquids.